[Hot Stock] SK Bioscience Rises on WHO Emergency Use Application for Korea's First Domestic COVID-19 Vaccine

[Asia Economy Reporter Myung-hwan Lee] SK Bioscience is on the rise in the market on the morning of the 8th. This appears to be due to the company's application for Emergency Use Listing (EUL) of Korea's first domestically developed COVID-19 vaccine to the World Health Organization (WHO).

As of 9:30 AM, SK Bioscience is trading at 106,000 KRW, up 2.91% (3,000 KRW) from the previous trading day.

SK Bioscience announced on the same day that it has completed the application for Emergency Use Listing (EUL) of 'Skycovione Multi,' Korea's first domestically developed COVID-19 vaccine, to the WHO. The WHO registers medicines that meet safety, efficacy, and quality standards on the EUL to rapidly supply vaccines and treatments during urgent health crises such as COVID-19. As of August this year, a total of 11 COVID-19 vaccines have been listed on the EUL.

Ahn Jae-yong, CEO of SK Bioscience, stated, "We will take the lead in responding to the COVID-19 endemic and securing global vaccine sovereignty by swiftly obtaining approvals from global institutions and countries."

This content was produced with the assistance of AI translation services.